Completed PHASE4 INTERVENTIONAL 1-arm NCT06043752

Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis

Efficacy and Safety of Infliximab Biosimilar Remsima in Treatment of Chronic Plaque Psoriasis

Sponsor: Ghurki Trust and Teaching Hospital

Conditions Psoriasis

Interventions Remsima

Updated 3 times since 2023 Last updated: Sep 12, 2023 Started: Mar 10, 2022 Primary completion: Jul 15, 2023 Completion: Aug 5, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Psoriasis and is currently completed. Ghurki Trust and Teaching Hospital leads this study, which shows 3 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Oct 2023 — Jul 2024 [monthly]

Completed PHASE4

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ghurki Trust and Teaching Hospital

Data source: Ghurki Trust and Teaching Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lahore, Pakistan